
Bayer invests into synthetic TCRs for cell therapy
Sometimes it's not bad to have old contacts like Jak Knowles, CEO of Boston-based Affini-T Therapeutics Inc., which left stealth mode at the J.P....

Biotalys’ first proteinbased biocontrol shows up in vineyards
Biotalys, the agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Argenx SE to raise €637m
Last December, the Breda-based drugmaker got the green lightfrom the US FDA for its injectible anti-acetylcholin receptor antibody fragment...

Mimetas BV participating in €325m cancer funding
As part of a financing of the Dutch Naional Growth Fund the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative has been granted...

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

Catalent swallows VMIC Ltd
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south...